Cronos Group Inc. Common Share (CRON) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Cronos Group Inc. Common Share (NASDAQ: CRON) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $3.36 (+0.30% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRON ranks #318 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), CRON carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 42.8%, and ROIC of -4.5%. By comparison, TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) holds a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, CRON leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).
Per CRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001656472), Cronos Group Inc. Common Share generated $146.6M in revenue (+24.6% YoY), -$2.9M in net income, and $149.0K in free cash flow against $1.20B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 81% of 52W Range • RSI-14 at 50.4 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($149.0K FCF) & 42.8% Gross Margin
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CRON currently carries a cautious 52/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.30) and Max Pain ($3.53) forces dealer call-delta covering toward $3.86.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cronos Group Inc. Common Share (CRON) advanced +0.30% to $3.36, trading at 81% of its 52-week range ($2.28 – $3.61). Stretched risk/reward at current multiples (-5% return on capital) under elevated 10-year interest-rate pressure.
AI enthusiasm in big tech has cooled as investors question heavy spending on data centers and chips. That pullback has shifted attention to smaller Canadian companies where every dollar is watched closely and balance she
Altria owns 42.5% of Cronos Group and 8.1% of AB InBev, providing a lower-risk backdoor play. A 5.9% dividend yield pays you to wait, but longer-dated calls might be better than the unusually active Nov. 20 calls.
US GDP growth running at a 3.4% annual pace puts risk assets back in focus, and that includes Canadian biotech stocks that can react sharply when money flows into higher risk ideas. Stronger US activity can support healt
With the Bank of Canada lifting its key interest rate and signaling that borrowing costs could rise further, cash now earns more and weak balance sheets matter more. That puts financially healthier penny stocks in a very
SNDL Inc. posted record free cash flow but faces near-term earnings pressure from restructuring and product cuts. Click for this earnings update of SNDL stock.
AI is soaking up massive amounts of capital right now, with Meta’s recent US$25 billion share sale reportedly drawing demand about five times larger than the deal size. That kind of appetite for growth stories can pull a
Energy prices are back in the spotlight as the Bank of Canada signals a possible rate hike to keep fuel driven inflation from spilling into everything from groceries to rent. Higher borrowing costs can punish heavily ind
Here is how Cronos Group (CRON) and Amgen (AMGN) have performed compared to their sector so far this year.
US tariffs on Canadian wood products are putting fresh pressure on parts of the domestic economy, which pushes some investors to look beyond the usual large caps. Solid Canadian penny stocks with cleaner balance sheets,
Rising global interest rates have made borrowing more expensive and pushed many investors toward safer balance sheets. That shift puts a spotlight on Canadian penny stocks that pair low share prices with relatively stron
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +24.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRON today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRON. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Cronos Group Inc. Common Share (CRON) ranks #318 by composite RQD confidence (52/100, grade D+) and #334 by equity capitalization ($1.24B). Within this direct 5-issuer industry benchmark cohort, CRON leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with CRON at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRON
ACTIVE
Cronos Group Inc. Common Share | D+ | 52/100 | — | 42.8% | -4.5% | +0.30% | $1.24B | Benchmark Subject |
| TRLV Trulieve Cannabis Corp. Subordinate Voting Shares | D+ | 58/100 | — | 60.2% | 12.8% | -0.19% | $2.04B | /trlv-vs-cron → |
| RGC Regencell Bioscience Holdings Limited | D- | 38/100 | — | — | — | -5.64% | $3.40B | /rgc-vs-cron → |
| TLRY Tilray Brands Inc. | E | 32/100 | — | 28.4% | -3.9% | -1.86% | $390.2M | /tlry-vs-cron → |
| OBIO Orchestra BioMed Holdings Inc. | E | 28/100 | — | 96.0% | -35.0% | +1.67% | $366.0M | /obio-vs-cron → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cronos Group Inc. Common Share (CRON) reported GAAP revenue of $146.6M (+24.6% vs. FY2024 revenue of $117.6M , and +68.0% cumulative change since FY2023) , GAAP net income of -$2.9M, operating cash flow of $25.9M, and free cash flow of $149.0K (-97.7% YoY). On the balance sheet, CRON closed FY2025 with $1.20B in total assets against $0 in total debt (Altman Z-Score: 15.20, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $146.6M | -$2.9M | $25.9M | $149.0K | $1.20B | — |
| FY2024 (FY) | 2024-12-31 | $117.6M | $40.0M | $18.8M | $6.4M | $1.17B | — |
| FY2023 (FY) | 2023-12-31 | $87.2M | -$73.9M | -$42.8M | -$42.8M | — | — |
As of 2026-11-01, Cronos Group Inc. Common Share (NASDAQ: CRON) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $3.36 (+0.30% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRON ranks #318 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), CRON carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 42.8%, and ROIC of -4.5%. By comparison, TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) holds a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, CRON leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).
Per CRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001656472), Cronos Group Inc. Common Share generated $146.6M in revenue (+24.6% YoY), -$2.9M in net income, and $149.0K in free cash flow against $1.20B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CRON last traded at $3.36 (+0.30% on volume of 666,408 shares), positioning the stock +1.82% above its 50-day simple moving average ($3.30) and +17.89% above its 200-day simple moving average ($2.85). Across its 52-week range of $2.28 to $3.61, CRON sits at the 81.2% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of ±5.6% ($3.17 to $3.55).
Why CRON Stock advanced +0.30% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-5% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.